Treatment of Hyperphosphatemia in Chronic Kidney Disease Stage 5 Receiving Dialysis with Hypercalcemia
Elevated serum phosphorus is common in end-stage kidney disease, and phosphate binder selection requires particular care when hypercalcemia is also present. The concurrent conditions shape which agents are clinically appropriate and carry implications for cardiovascular risk.
This protocol applies to patients with chronic kidney disease (CKD) stage 5 who are receiving dialysis and in whom hypercalcemia is present. In this setting, hypercalcemia can increase the risk of cardiovascular disease — making the choice of phosphate binder a clinically consequential decision beyond phosphorus control alone.
Treatment Approach
Management relies on a class of non-calcium-based phosphate binders, selected specifically to avoid worsening hypercalcemia. Agents in this class have demonstrated a cardiovascular mortality benefit in this clinical context. The complete evidence-based regimen — including specific agent selection and clinical considerations — is available via the structured protocol below.
Clinical Target: Achieve a serum phosphorus concentration of 3.5 to 5.5 mg/dL.
References
- In CKD stage 5, hypercalcemia can increase the risk of cardiovascular disease.
- Sevelamer and lanthanum can be used in the setting of hypercalcemia, and they offer a cardiovascular mortality benefit.
- In this situation, sevelamer and lanthanum have demonstrated a cardiovascular mortality benefit.
- The target phosphorus concentration for dialysis patients is 3.5 to 5.5 mg/dL.
View source ↗